01—Abstract
Summary
Summary of the 8-K filed June 8, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation (INCY) reported in a Form 8-K dated June 8, 2026 that it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC.
Incyte will pay $1.25 billiona upfront, and Star Therapeutics will be eligible to receive up to $750 million in additional payments upon achievement of sales milestones, for total potential consideration of up to $2.0 billion, subject to customary closing adjustments. The transaction is structured as an equity (stock purchase) acquisition. The core asset is VGA039, a novel investigational monoclonal antibody that targets Protein S and is in Phase 3 development for von Willebrand disease (VWD), described as the most common inherited bleeding disorder.
The company states VGA039 has received FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations and is being studied in the Phase 3 VIVID-6 trial. The filing states it could be the first subcutaneous prophylactic therapy with a convenient dosing regimen for VWD patients who currently require frequent intravenous infusions. The transaction is expected to close in the third quarter of 2026, subject to expiration of the Hart-Scott-Rodino waiting period and other customary conditions.
Incyte expects an R&D charge of approximately $1.25 billionb, to be included in third quarter and full year 2026 GAAP and non-GAAP results. Incyte's CEO Bill Meury said the deal fits the company's strategy of building a top-tier growth company and expands its hematology portfolio.
02—Key points
Key Highlights
- Incyte agreed to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion upfront.
- Up to $750 million in additional payments are contingent on sales milestones, for total potential consideration of up to $2.0 billion.
- The core asset, VGA039, is a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease, with a potential once-monthly subcutaneous dosing regimen.
- VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations.
- Closing is expected in the third quarter of 2026, subject to HSR antitrust waiting period expiration and other customary conditions.
- Incyte expects an approximately $1.25 billion R&D charge in third quarter and full year 2026 GAAP and non-GAAP results.
- The filing states approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.
03—Questions
Frequently Asked Questions
What is Incyte acquiring and for how much?
Incyte agreed to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion upfront, with up to $750 million more in sales-milestone payments, for total potential consideration of up to $2.0 billion, subject to customary closing adjustments.
What is VGA039 and what disease does it target?
VGA039 is an investigational monoclonal antibody that modulates Protein S to improve hemostasis. It is in Phase 3 development for von Willebrand disease, the most common inherited bleeding disorder, and the filing says it has the potential to be the first subcutaneous prophylactic therapy with a convenient dosing regimen for these patients.
When is the transaction expected to close and what are the conditions?
The transaction is expected to close in the third quarter of 2026. Closing is subject to expiration of the Hart-Scott-Rodino Antitrust Improvements Act waiting period and other customary conditions.
What financial impact does Incyte expect from the deal?
Incyte expects an R&D charge of approximately $1.25 billion, which will be included in its third quarter and full year 2026 GAAP and non-GAAP results.
What did Incyte's CEO say about the acquisition?
CEO Bill Meury said VGA039 fits directly into Incyte's strategy of building a top-tier growth company, calling it a first-in-class, Phase 3 asset with compelling early data and a manageable development path, with potential to become an important new growth driver in hematology.
04—Continue